High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
Cancer Cell International,
Abstract Background Adaptive resistance and side effects of sorafenib treatment result in unsatisfied survival of patients with…